N@N

Peregrine Pharmaceuticals to Present at the Rodman & Renshaw Sixth Annual Global Investment Conference

^{Published on 2010-05-10 06:10:27 - Market Wire}
 

TUSTIN, CA--(Marketwire - May 10, 2010) - Peregrine Pharmaceuticals, Inc. (NASDAQ: [ PPHM ]), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the Rodman & Renshaw Sixth Annual Global Investment Conference in London on Tuesday, May 18, 2010 at 10:40 am BST (5:40 am EDT). The conference will be held at the Grosvenor House Hotel in London, UK.

A live webcast of the company's presentation will be available in the Investors section of Peregrine's website at [ http://www.peregrineinc.com ]. A replay will be available on the Peregrine website and will be archived for 30 days.

For more information about this conference, please visit:
[ http://www.rodmanandrenshaw.com/conferences?id=44 ].

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara^®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].